MA55976A - Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide - Google Patents

Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide

Info

Publication number
MA55976A
MA55976A MA055976A MA55976A MA55976A MA 55976 A MA55976 A MA 55976A MA 055976 A MA055976 A MA 055976A MA 55976 A MA55976 A MA 55976A MA 55976 A MA55976 A MA 55976A
Authority
MA
Morocco
Prior art keywords
fluorocyclopropyl
oxadiazol
imidazo
carboxamide
methylphenyl
Prior art date
Application number
MA055976A
Other languages
English (en)
Inventor
Andreas Kordikowski
Xiaoyang Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA55976A publication Critical patent/MA55976A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA055976A 2019-05-13 2020-05-13 Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide MA55976A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2019086582 2019-05-13

Publications (1)

Publication Number Publication Date
MA55976A true MA55976A (fr) 2022-03-23

Family

ID=73289607

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055976A MA55976A (fr) 2019-05-13 2020-05-13 Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide

Country Status (14)

Country Link
US (1) US20220194936A1 (fr)
EP (1) EP3969453A4 (fr)
JP (1) JP2022533340A (fr)
KR (1) KR20220007650A (fr)
CN (1) CN114096538A (fr)
AU (1) AU2020274564A1 (fr)
BR (1) BR112021022685A2 (fr)
CA (1) CA3139552A1 (fr)
IL (1) IL287877A (fr)
MA (1) MA55976A (fr)
MX (1) MX2021013814A (fr)
SG (1) SG11202112281UA (fr)
TW (1) TW202108581A (fr)
WO (1) WO2020228746A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534963A (ja) 2020-07-15 2023-08-15 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の結晶質形態
WO2022106615A1 (fr) * 2020-11-19 2022-05-27 Novartis Ag Compositions pharmaceutiques d'un inhibiteur sélectif de la kinase c-kit et leurs procédés de fabrication et d'utilisation
JP2023551434A (ja) * 2020-11-19 2023-12-08 サード ハーモニック バイオ， インコーポレイテッド 選択的ｃ－ｋｉｔキナーゼ阻害剤の医薬組成物ならびにその作製および使用のための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014004319A2 (pt) * 2011-09-01 2017-03-14 Irm Llc compostos e composições como inibidores de c-kit cinase
US9199981B2 (en) * 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
WO2013033203A1 (fr) * 2011-09-01 2013-03-07 Irm Llc Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit
KR101962495B1 (ko) * 2011-09-01 2019-03-26 노파르티스 아게 C-kit 키나제 억제제로서의 화합물 및 조성물

Also Published As

Publication number Publication date
WO2020228746A1 (fr) 2020-11-19
EP3969453A4 (fr) 2023-01-18
TW202108581A (zh) 2021-03-01
SG11202112281UA (en) 2021-12-30
JP2022533340A (ja) 2022-07-22
AU2020274564A1 (en) 2021-12-09
IL287877A (en) 2022-01-01
BR112021022685A2 (pt) 2022-03-29
CA3139552A1 (fr) 2020-11-19
CN114096538A (zh) 2022-02-25
KR20220007650A (ko) 2022-01-18
EP3969453A1 (fr) 2022-03-23
US20220194936A1 (en) 2022-06-23
MX2021013814A (es) 2022-02-10

Similar Documents

Publication Publication Date Title
MA55976A (fr) Formes cristallines de n-(5-(5-((1r, 2s)-2-fluorocyclopropyl)-1,2,4-oxadiazol-3-yl)-2-methylphenyl) imidazo [1,2-a] pyridine-3-carboxamide
DK3800189T3 (da) Fremstilling af (s)-n-(5-((r)-2-(2,5-difluorphenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamid
EA201990518A1 (ru) Производные пиразолопиридина, обладающие эффектом агониста рецептора glp-1
MA54755A (fr) Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
DK2361609T3 (da) Formulering af småmolekylære lægemidler med forsinket frigivelse
AR078766A1 (es) Formas solidas de n-(4-(7-azabiciclo(2.2.1) heptan-7-il)-2-( trifluorometil) fenil)-4-oxo-5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
CL2013000351A1 (es) Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias.
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
WO2016020320A8 (fr) 2- (morpholin -4-yl)-l,7-naphtyridines
GT200900014A (es) Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.
IL259387A (en) Mesoionic halogenated 3-(acetyl)-1-[(1,3-thiazol-5-yl)methyl]-1h-imidazo[1,2-a]pyridin-4-ium-2-olate derivatives and related compounds as insecticides
DK3625233T5 (da) 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylpropanoat-derivativer og relaterede forbindelser som peroralt indgivne prodrugs af beta-lactamase-inhibitorer til behandling af bakterielle infektioner
BR112014028395A2 (pt) derivados 3,4-di-hidro-2h-pirido[1,2-a] pirazina-1,6-diona substituídos úteis para o tratamento de (inter alia) doença de alzheimer
WO2009050352A3 (fr) Derives d'imidazolones, procede de preparation et applications biologiques
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
DK3840832T3 (da) Imidazo[1,2-b]pyridaziner som trk-inhibitorer
NO20075482L (no) Propan-1,3-dionderivat og salt derav
EA202190405A1 (ru) КРИСТАЛЛИЧЕСКИЙ ПОЛИМОРФ 8-БРОМ-2-(1-МЕТИЛПИПЕРИДИН-4-ИЛАМИНО)-4-(4-ФЕНОКСИФЕНИЛАМИНО)ПИРИДО[4,3-d]ПИРИМИДИН-5(6H)-ОН ГИДРОХЛОРИДА И СПОСОБ ЕГО ПОЛУЧЕНИЯ
PH12016502405A1 (en) 2-acylaminothiazole derivative or salt thereof
DK3737684T3 (da) 2,4,6,7-tetrahydro-pyrazolo[4,3-d]pyrimidin-5-on-derivater og relaterede forbindelser som c5a-receptormodulatorer til behandling af vaskulitis og inflammatoriske sygdomme
PE20190204A1 (es) [8-(fenilsulfonil)-3,8-diazabiciclo[3.2.1]oct-3-il](1h-1,2,3-triazol-4-il)metanonas
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
EA201890896A1 (ru) Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения
CL2007002732A1 (es) Compuestos derivados de pirrolizina, indolizina y quinolizina; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de trastornos asociados a demencia, psicosis y esquizofrenia.
IL281025A (en) Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-inol)-pyrrolidine-2-YL]imidazo[1,5-A]-pyrazine-1-YL}N- (pyridine-2-YL)-benzamide